Holen Sie sich die Stockscreener-App
9.68
5.38%
-0.55
Schlusskurs vom Vortag:
$10.23
Offen:
$10.35
24-Stunden-Volumen:
2.55M
Relative Volume:
1.49
Marktkapitalisierung:
$692.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.98M
KGV:
-10.52
EPS:
-0.9199
Netto-Cashflow:
$-32.77M
1W Leistung:
-11.76%
1M Leistung:
-30.66%
6M Leistung:
+8.28%
1J Leistung:
+360.95%
1-Tages-Spanne:
$9.48
$10.37
1-Wochen-Bereich:
$9.48
$11.85
52-Wochen-Spanne:
$1.9949
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
9.68 | 784.79M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-09 | Eingeleitet | Mizuho | Outperform |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Law firms investigate Immix Biopharma after executive termination - scanx.trade
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma closes $117.1m stock offering - Investing.com
Immix Biopharma Closes $125 Million Stock Offering - marketscreener.com
Immix Biopharma closes $117.1m stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Citizens reiterates Immix Biopharma stock rating on trial data - Investing.com
Immix Bio offering to raise USD 125m after 89% CR rate for BCMA CAR T in amyloidosis - AllSci
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock - Yahoo Finance
Needham maintains Buy rating on Immix Biopharma, $30 price target - TradingView
Form 8K Immix Biopharma Inc For: 29 September By Investing.com - Investing.com Nigeria
Needham initiates coverage on Immix Biopharma with Buy rating - scanx.trade
Immix Biopharma prices $125M stock offering at $11.00 per share - scanx.trade
IMMX: NXC-201 delivers rapid, deep, and durable responses with strong safety in AL amyloidosis - TradingView
Transcript : Immix Biopharma, Inc.Shareholder/Analyst Call - marketscreener.com
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial - Yahoo Finance
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Immix posts new trial data for AL amyloidosis drug (IMMX) - Seeking Alpha
Form 424B5 Immix Biopharma Inc For: 29 September By Investing.com - Investing.com Nigeria
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com Nigeria
Immix Biopharma Prices $125 Million Stock Offering - marketscreener.com
Immix Biopharma reports 89% complete response rate in trial By Investing.com - Investing.com Nigeria
Immix Biopharma reports promising interim Phase 2 results - TipRanks
Immix Biopharma prices $125M stock offering - TradingView
IMMX: Interim results show an 89% complete response rate in AL Amyloidosis, with potential to reach 98% - TradingView
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
Immix plans to use about $117 million for treatment development and company operations - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Global BMI Index - marketscreener.com
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion - Investing.com India
IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead - TradingView
IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval - TradingView
Immix Biopharma at Morgan Stanley conference: CAR T push gains pace - Investing.com Canada
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
IMMX Q2 2026 Earnings: Modest EPS Miss Signals Continued Clinical-Stage InvestmentEarnings Yield Analysis - dars.gov.et
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Immix (IMMX) Latest: Ends Higher by 3.80% at $13.66 in Latest Trading; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in Latest TradingBullish Pattern Stocks - dars.gov.et
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immix Biopharma Inc-Aktie (IMMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):